Despite advances in surgery, radiation, and medical therapy over the past decade and the widespread adoption of PSA screening, prostate cancer continues to be the second leading cause of cancer death in men in the United States.
Invasive cancer is the end result of carcinogenesis, a chronic process occurring over many years driven by genetic and epigenetic alterations. The protracted nature of this transformation to the malignant phenotype provides an opportunity to intervene pharmacologically to prevent, reverse, or delay carcinogenesis, i.e. chemoprevention. Herein, we describe the unique features of cancer prevention, as opposed to cancer treatment, agent development clinical trials, and provide a summary of the ongoing research in this field being supported by the National Cancer Institute.
Written by:
Parnes HL, House MG, Tangrea JA. Are you the author?
Division of Cancer Prevention, 9609 Medical Center Drive, National Cancer Institute, Bethesda, MD, 20892-9783, USA.
Reference: Recent Results Cancer Res. 2014;202:121-31.
doi: 10.1007/978-3-642-45195-9_15
PubMed Abstract
PMID: 24531786
UroToday.com Prostate Cancer Section
